Roche invests $387M in biotech

Like so many other pharmaceutical industry giants, Roche has announced plans to increase its stake in biotech, pledging to invest $430 million Swiss francs ($387 million) in three sites in Switzerland and Germany. Around 280 million francs will be invested in expanding biotech R&D efforts at Roche's Penzberg, Germany site, specifically in the area of oncology. An additional 150 million francs will be invested at Mannheim and Kaiseraugst in expanding modern syringe filling capacities for drugs such as Mircera, Pegasys or Actemra.

"With our biopharmaceuticals heavily in demand, this step will both safeguard and expand production. Investments like this are very much long term in nature and they create hundreds of jobs in and around the company. It is therefore essential that a stable, industry-friendly environment be maintained in the long term," said CEO Franz Humer in a statement. 

- see this release for more

ALSO: Take a look at Roche's pipeline. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.